Please use this identifier to cite or link to this item:
http://hdl.handle.net/2445/200879
Title: | Estimating the Prevalence of Cardiac Amyloidosis in Old Patients with Heart Failure—Barriers and Opportunities for Improvement: The PREVAMIC Study |
Author: | Ruiz Hueso, Rocío Salamanca Bautista, Prado Quesada Simón, Maria Angustias Yun, Sergi Conde Martel, Alicia Morales Rull, José Luis Suárez Gil, Roi García García, José Ángel Llàcer, Pau Fonseca Aizpuru, Eva María Amores Arriaga, Beatriz Martínez González, Ángel Armengou Arxe, Arola Peña Somovilla, José Luis López Reboiro, Manuel Lorenzo Aramburu Bodas, Óscar PREVAMIC Investigators Group |
Keywords: | Amiloïdosi Insuficiència cardíaca Epidemiologia Amyloidosis Heart failure Epidemiology |
Issue Date: | 15-Mar-2023 |
Publisher: | MDPI AG |
Abstract: | Background: Cardiac amyloidosis (CA) could be a common cause of heart failure (HF). The objective of the study was to estimate the prevalence of CA in patients with HF. Methods: Observational, prospective, and multicenter study involving 30 Spanish hospitals. A total of 453 patients >= 65 years with HF and an interventricular septum or posterior wall thickness > 12 mm were included. All patients underwent a Tc-99m-DPD/PYP/HMDP scintigraphy and monoclonal bands were studied, following the current criteria for non-invasive diagnosis. In inconclusive cases, biopsies were performed. Results: The vast majority of CA were diagnosed non-invasively. The prevalence was 20.1%. Most of the CA were transthyretin (ATTR-CM, 84.6%), with a minority of cardiac light-chain amyloidosis (AL-CM, 2.2%). The remaining (13.2%) was untyped. The prevalence was significantly higher in men (60.1% vs 39.9%, p = 0.019). Of the patients with CA, 26.5% had a left ventricular ejection fraction less than 50%. Conclusions: CA was the cause of HF in one out of five patients and should be screened in the elderly with HF and myocardial thickening, regardless of sex and LVEF. Few transthyretin-gene-sequencing studies were performed in older patients. In many patients, it was not possible to determine the amyloid subtype. |
Note: | Reproducció del document publicat a: https://doi.org/10.3390/jcm12062273 |
It is part of: | Journal of Clinical Medicine, 2023, vol. 12, num. 6, p. 2273 |
URI: | http://hdl.handle.net/2445/200879 |
Related resource: | https://doi.org/10.3390/jcm12062273 |
ISSN: | 2077-0383 |
Appears in Collections: | Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL)) |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
jcm-12-02273-v2.pdf | 1.1 MB | Adobe PDF | View/Open |
This item is licensed under a
Creative Commons License